1CP
SMMT icon

1015 Capital Partners’s Summit Therapeutics SMMT Stock Holding History

1015 Capital Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58 Sell
4
-6
-60% -$106 ﹤0.01% 608
2026
Q1 		$190 Buy
10
+9
+900% +$146 ﹤0.01% 576
2025
Q4 		$17 Buy
+1
New +$19 ﹤0.01% 630

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

1015 Capital Partners's SMMT Position: Q2 2026 in Review

1015 Capital Partners reduced its Summit Therapeutics (SMMT) stake by 60% in Q2 2026, selling an estimated $106 and leaving 4 shares worth $58. The position accounts for ﹤0.01% of the portfolio, ranked #608.

1015 Capital Partners first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. The position peaked at $190 in Q1 2026. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • 1015 Capital Partners held 4 shares of Summit Therapeutics worth $58 as of Q2 2026.
  • 1015 Capital Partners sold 6 Summit Therapeutics shares in Q2 2026, an estimated $106.
  • Summit Therapeutics made up ﹤0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #608 holding.
  • 1015 Capital Partners first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 1015 Capital Partners's Summit Therapeutics position peaked at $190 in Q1 2026.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.